Project Grant R01CA289761
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$490K
Federal Agency
National Cancer Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanism by which a gene essential for rhabdoid tumor viability regulates chromatin function. The award, totaling $148,568, will be used by the prime awardee, St. Jude Children's Research Hospital Inc., to conduct molecular and genome-wide studies to assess the regulation of chromatin by this gene, which has been found to repress polycomb function and may...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), is supporting research aimed at developing effective therapeutic strategies for lung cancers with SMARCA4 genetic deficiencies. The primary grantee, The Trustees of Columbia University in the City of New York, will receive $557,418 over the award period from March 2025 to February 2030. The research will use genetically engineered mouse models to assess the impact of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $942,442 in funding to the Dana-Farber Cancer Institute, Inc. over the period of September 1, 2024 to August 31, 2031. The goal of this research is to identify the mechanisms driving rapid evolution of cancer genomes, particularly through processes like chromothripsis and chromoplexy. The project will leverage single-cell genomics methods developed by the...
This Project Grant award from the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396) provides $583,127 to the Sloan-Kettering Institute for Cancer Research to investigate the mechanisms by which SMARCA4 deficiency promotes metastasis in lung adenocarcinoma (LUAD). The research aims to elucidate how the ROR2/p-GSK3Bβ signaling pathway regulates transcription and metastasis in SMARCA4-deficient LUAD, and to evaluate the therapeutic potential of targeting ROR2 to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $452,549.00 to Emory University to conduct research on targeting intrinsic and extrinsic features of MYC-driven osteosarcoma. The key objectives are to:
Comprehensively characterize and genetically perturb cross-species molecular features of MYC-hyperactivated human and murine osteosarcoma tumors to identify intrinsic and extrinsic signatures and cell-cell...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $336,000 to the Van Andel Research Institute (VAI) to characterize the role of germline genetic variation and viral exposures as determinants of susceptibility to hematological diseases, particularly pediatric acute myeloid leukemia (AML). The research aims to identify genetic and viral factors that may interact with structural chromosomal variants to increase the risk of AML and...
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
This Project Grant award of $225,101 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to investigate the mechanisms underlying the increased risk of hematological malignancy in sickle cell disease (SCD). The research aims to understand how oxidative stress-induced DNA damage in hematopoietic stem and progenitor cells (HSPCs) contributes to the development of clonal hematopoiesis and hematological malignancies in SCD,...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), supports innovative research by Cold Spring Harbor Laboratory (CSHL) to define the epigenetic mechanism by which targeting the chromatin regulator BRD8 re-establishes p53-mediated tumor suppression in glioblastoma (GBM) lacking p53 mutations. The key objectives are to: 1) characterize the genomic and epigenomic features of p53 target genes activated by the...
This $898,660 project grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research into the role of SWI/SNF chromatin remodelers in homologous recombination and genome stability. The grant is awarded under the Cancer Cause and Prevention Research program (CFDA 93.393), which supports identification of cancer risks and mechanisms for prevention.
The Midwestern University project will further define the mechanisms by which BRG1 and BRM...